|
HIGHLIGHTS FROM ICAAC
�97 FORTOVASETM + VIRACEPT�
Combination Regimen
Dr. S. Kravcik of Ottawa General Hospital,
Ottawa, Canada, presented data on the interaction between two protease inhibitor
therapies, FORTOVASE, the investigational soft gel formulation of saquinavir, and VIRACEPT
in advanced HIV disease. Study subjects with CD4 counts between 25 and 500 and HIV RNA
>20,000 copies were enrolled and placed on a combination of FORTOVASE + VIRACEPT. Week
16 data showed a median viral load drop of 2.05 log10 and a CD4 rise of 117.5.
Eight of 13 subjects had a viral load < 500; four other subjects with higher viral
loads were non-complaint with study medications. When examined for specific HIV RNA
mutations, none of the subjects possessed the D30N mutation associated with VIRACEPT
resistance and only four possessed mutations associated with decreased sensitivity to
FORTOVASE. This study showed that the combination of FORTOVASE and VIRACEPT produces
durable HIV suppression, is well tolerated, and does not give rise to new mutations.
Table of Contents
|
|
